- Home
- BWLP vs IRON Comparison
BWLP vs IRON Comparison
Compare BWLP & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- IRON
- Stock Information
- Founded
- BWLP 1935
- IRON 2017
- Country
- BWLP Singapore
- IRON United States
- Employees
- BWLP N/A
- IRON N/A
- Industry
- BWLP Marine Transportation
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- BWLP Consumer Discretionary
- IRON Health Care
- Exchange
- BWLP Nasdaq
- IRON Nasdaq
- Market Cap
- BWLP 1.6B
- IRON 1.4B
- IPO Year
- BWLP N/A
- IRON N/A
- Fundamental
- Price
- BWLP $10.47
- IRON $46.68
- Analyst Decision
- BWLP
- IRON Strong Buy
- Analyst Count
- BWLP 0
- IRON 9
- Target Price
- BWLP N/A
- IRON $93.89
- AVG Volume (30 Days)
- BWLP 417.3K
- IRON 341.5K
- Earning Date
- BWLP 05-20-2025
- IRON 05-07-2025
- Dividend Yield
- BWLP 16.22%
- IRON N/A
- EPS Growth
- BWLP N/A
- IRON N/A
- EPS
- BWLP 1.86
- IRON N/A
- Revenue
- BWLP $3,387,328,000.00
- IRON N/A
- Revenue This Year
- BWLP N/A
- IRON N/A
- Revenue Next Year
- BWLP $2.04
- IRON N/A
- P/E Ratio
- BWLP $5.99
- IRON N/A
- Revenue Growth
- BWLP 9.53
- IRON N/A
- 52 Week Low
- BWLP $7.86
- IRON $30.82
- 52 Week High
- BWLP $22.31
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- BWLP 47.47
- IRON 49.90
- Support Level
- BWLP $10.60
- IRON $44.85
- Resistance Level
- BWLP $10.98
- IRON $47.36
- Average True Range (ATR)
- BWLP 0.29
- IRON 2.23
- MACD
- BWLP -0.08
- IRON -0.12
- Stochastic Oscillator
- BWLP 12.40
- IRON 37.58
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.